The Immuno-oncology (I-O) Focus on VJHemOnc is supported by Johnson & Johnson. This supporter has no influence over the production of the content.
Welcome to the Immuno-Oncology (I-O) Focus
Explore the latest updates in this field by hematological disease and therapy type. I-O Focus showcases expert interviews and discussions, podcasts and e-learning.
I-O is at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Agents including antibodies, immune checkpoint inhibitors, NK cells, vaccines and CAR-T cells are increasingly featured in treatment regimens, many of which are under testing in clinical trials currently. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.